

10/075,954

- 13 -

Charles Andrianjara et al.

REMARKS**Claim Status**

Claims 1, 3, 4, 9, 12-15 and 29 would be all the claims pending if this amendment is entered.

Claims 3, 4, 9, 12-14 and 29 have been amended.

Claims 37-39 have been canceled.

Preliminary Remarks

Applicants note with appreciation that claims 1 and 15 have been allowed. In the Office Action it was noted that there was an inconsistency with regard to the cancellation of claims 30-36. Applicants affirm that claims 30-36 have been canceled.

35 U.S.C. 112, § Second Paragraph

Claims 3, 4, 9, 12-14 and 37-39 have been rejected under 35 U.S.C. § 112, second paragraph as allegedly unpatentable for being indefinite because of the use of the word "characterized." Claims 3, 4, 9, 12-14 have been amended to delete the word "characterized" and use the more common word "wherein." Claims 37-39 have been canceled.

Claims 29 and 37 have been rejected because they refer to claim 11, which has been canceled. Claim 29 has been amended to delete the reference to claim 11. Claim 37 has been canceled.

35 U.S.C. §112, First Paragraph

Claims 37-39 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly not being enabled. While applicants disagree and believe that claims 37-39 are fully enabled, in order to expedite prosecution, applicants have canceled

10/075,954

- 14 -

Charles Andrianjara et al.

claims 37-39 and reserve the right to prosecute the claims in a continuation or divisional application.

In view of the amendments and remarks made above, applicants believe that this application is in condition for allowance. Reconsideration and allowance of claims 1, 3, 4, 9, 12-15 and 29 is respectfully requested.

Respectfully submitted,

Date: _____



Todd M. Crissey
Reg. No. 37,807
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7813
Fax (734) 622-1553